 |
|
|
 |
|
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date: October 25, 2011
Client: S*BIO
Summary: SINGAPORE, Oct. 25, 2011 - S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.
|
|
|
|
 |
|
Brinson Patrick Securities Develops Life Sciences Advisory Board
Date: October 25, 2011
Client: Brinson Patrick
Summary: NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Brinson Patrick Securities, a boutique investment bank that focuses specifically on at-the-market (ATM) offerings, today announced that Gregory Hanson and Jack Florio have been appointed as advisors and will join its current advisor, Vivian Liu, in the development of a life sciences advisory board. The advisory board will provide Brinson Patrick's management team with additional perspective and understanding of the financial needs of the emerging life sciences community and will help Brinson Patrick to expand its offerings in this important industry sector. All three have many years of experience helping life sciences companies raise capital.
|
|
|
|
 |
|
Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection
Date: October 24, 2011
Client: GlobeImmune, Inc.
Summary: Foster City, CA and Louisville, CO - October 24, 2011 - Gilead Sciences, Inc. (Nasdaq: GILD) and GlobeImmune, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.
|
|
|
|
 |
|
Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
Date: October 24, 2011
Client: Regulus Therapeutics
Summary: LA JOLLA, Calif., October 24, 2011 - Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, will host this week a webinar that focuses on the potential of microRNA-33 as a target for the treatment of atherosclerosis. The discussion will involve pre-clinical research findings that demonstrate microRNA-33's key role in cholesterol homeostasis and fatty acid metabolism. These findings were published last week in Nature (Rayner et al., Nature, October 20, 2011).
|
|
|
|
 |
|
Panic! No, don't panic! ECJ embryonic stem cells ruling divides opinion
Date: October 24, 2011
Client: Cellular Dynamics International
Summary: One set of interested parties has loudly bemoaned the European Court of Justice's ruling that embryonic stem cells cannot be patented, lamenting that it will stifle investment in research in the sector and lead to a shift in commercial development away from Europe.
|
|
|
|
|
|
Regulus Therapeutics and Collaborators Publish New Pre-clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Date: October 20, 2011
Client: Regulus Therapeutics
Summary: LA JOLLA, Calif., October 20, 2011 - Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011). |
|
|
|
 |
|
Additional Data on the Mechanistic Characterization of Adverse Events of Voriconazole and Telithromycin to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA)
Date: October 20, 2011
Client: Cempra Pharmaceutical
Summary: Boston, Oct. 20, 2011 - Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The data will be presented during a poster abstract session at 12:15 to 2:15 p.m. EDT on October 21 in Poster Hall B1.
|
|
|
|
 |
|
Making Heart Cells—Billions of Them
Date: October 17, 2011
Client: Cellular Dynamics International
Summary: Researcher James Thomson achieved a scientific breakthrough a few years ago when he found a way to access stem cells without destroying embryos. He also saw an opportunity to make it a business.
|
|
|
|
 |
|
Cellular Dynamics International's (CDI) Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards
Date: October 17, 2011
Client: Cellular Dynamics International
Summary: MADISON, Wis., Oct. 17, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it was named as the overall Gold winner in The Wall Street Journal Technology Innovation Awards. The Wall Street Journal 2011 Technology Innovation Awards are determined by a panel of independent judges who evaluated significant innovations that occurred in 2010. Six-hundred-five applicants competed for the award in 16 categories. Of these, the panel chose 35 winners and runners-up.
|
|
|
|
 |
|
Anadys Announces Agreement To Be Acquired By Roche
Date: October 17, 2011
Client: Anadys Pharmaceuticals, Inc
Summary: SAN DIEGO, Oct. 17, 2011 - Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.
|
|
|
|
 |
|
Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
Date: October 17, 2011
Client: Sutro Biopharma
Summary: SAN FRANCISCO, Oct. 17, 2011 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company's proprietary biochemical protein synthesis technology platform for the synthesis and manufacturing of novel protein therapeutics will be presented at the BioProduction 2011 conference in Berlin.
|
|
|
|
 |
|
A Painkiller for Equity Issuers
Date: October 13, 2011
Client: Brinson Patrick
Summary: With the S&P 500 still 60 points or so off from where it started 2011, CFOs don't want to do anything to give investors jitters over a dropping share price. A huge one-time share issue can do just that. If a company doesn't need to raise a large amount of capital in a short period, though, an "at-the-market" (ATM) offering just might suffice.
|
|
|
|
 |
|
ATM cash for biotechs
Date: October 13, 2011
Client: Brinson Patrick
Summary: In August, Somaxon Pharmaceuticals chose an alternative strategy to raise $30 million, and in June, BioCryst Pharmaceuticals of Research Triangle Park, North Carolina, used a similar tactic to raise $70 million. Both companies raised money through at-the-market (ATM) offerings, a financing tool that was not used at all in the biotech industry as recently as 2005. Since then, ATMs have been rapidly gaining favor. According to the New York-based investment bank Brinson Patrick Securities, which specializes in ATMs, by 2010 the number of ATM offerings had grown to 26 in the biotech sector (raising $184 million), nearly tripling the 9 that took place in 2009. This year there have been 15 so far.
|
|
|
|
 |
|
The Prostate Cancer Foundation and Exosome Diagnostics Collaborate to Accelerate Clinical Validation of Exosome Biofluid Molecular Diagnostics in Prostate Cancer
Date: October 13, 2011
Client: Exosome Diagnostics
Summary: SANTA MONICA, CA, and NEW YORK October 13, 2011 - The Prostate Cancer Foundation (PCF) and Exosome Diagnostics today are announcing a multi-year collaboration to accelerate clinical validation of Exosome's biofluid molecular diagnostics technology in prostate cancer. In addition, Howard Soule, Ph.D., chief science officer of PCF, will join the Exosome Diagnostics Scientific Advisory Board.
|
|
|
|
|
|
Anadys Announces Positive 12-Week Data for Setrobuvir in Phase 2b Hepatitis C Study
Date: October 13, 2011
Client: Anadys Pharmaceuticals, Inc
Summary: SAN DIEGO, October 13, 2011 - Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients. Setrobuvir is the Company's direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV.
|
|
|
|
|
|
Cempra Holdings, LLC Files Registration Statement for Proposed Initial Public Offering
Date: October 12, 2011
Client: Cempra Pharmaceuticals
Summary: CHAPEL HILL, N.C., Oct. 12, 2011 /PRNewswire/ -- Cempra Holdings, LLC, the parent holding company of Cempra Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to its proposed initial public offering.
|
|
|
|
 |
|
AbD Serotec, Moredun Research Institute and Roslin Institute Announce Grant Funding to Establish Veterinary Research Reagents
Date: October 12, 2011
Client: MorphoSys AG
Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec business unit entered into an agreement with the Moredun Research Institute and the Roslin Institute at The University of Edinburgh to establish a broad range of research reagents in the veterinary research arena. The project is funded through an Industrial Partnership Award from the Biotechnology and Biological Sciences Research Council (BBSRC) under a joint initiative with the Scottish Government's Rural and Environment Science and Analytical Services Division (RESAS). Over the three-year term of the grant, the Moredun Research Institute and Roslin Institute combined will receive funding of nearly GBP 1 million.
|
|
|
|
 |
|
Cougar founder snags Pfizer cancer drug, raises $55M and launches new biotech
Date: October 6, 2011
Client: Cougar Biotechnology
Summary: The former CEO and founder of Cougar Biotechnology, Alan Auerbach, is back in the business of developing cancer drugs. In a series of maneuvers unveiled yesterday, Auerbach's Puma Biotechnology acquired a shell company and went public in a reverse merger, raised $55 million in a private placement, inked a deal for the rights to a late-stage cancer drug from Pfizer ($PFE) and scrapped two clinical studies as he changed the development strategy.
|
|
|
|
 |
|
New company Puma roars with Pfizer licensing deal
Date: October 6, 2011
Client: Puma Biotechnology
Summary: Alan Auerbach continues his big cat obsession. Two years after selling Cougar Biotechnology to Johnson & Johnson for nearly $1bn, primarily for prostate cancer drug Zytiga, Mr. Auerbach's new company Puma Biotechnology has licensed from Pfizer the rights to breast cancer treatment neratinib.
|
|
|
|
 |
|
The Japanese Cancer Association and Debiopharm Group™ present Doctors Arakawa and Kurokawa with the 2011 ‘JCA-Mauvernay Award’for their innovative and outstanding research in the field of cancer
Date: October 5, 2011
Client: Debiopharm Group
Summary: Lausanne, Switzerland - October 5, 2011 - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the 'JCA-Mauvernay Award' to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the 'identification and characterisation of p53 target genes' and to Doctor Mineo Kurokawa from the University of Tokyo, for his applied research on 'the molecular pathogenesis and therapeutic targets of hematological malignancies'. The ceremony was held during the 70th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya, Japan. This year the theme was 'Forward Strides for Cancer Research - Grounds for a Confident Future'. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group presented both scientists with the 2011 Award for their outstanding and innovative research.
|
|
|
|
 |
|
ACT Chairman and CEO Gary Rabin to Present at World Stem Cell Summit
Date: October 5, 2011
Client: Advanced Cell Technology
Summary: MARLBOROUGH, Mass. - Oct. 3, 2011 - Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company's chairman and CEO, Gary Rabin, will be presenting at the 2011 World Stem Cell Summit on Wednesday, Oct. 5, at the Pasadena Convention Center in Pasadena, Calif.
|
|
|
|
|
